MYCN and neuroblastoma: Most patients (n = 13, 76.5%) had INSS stage 4 neuroblastoma at diagnosis, including three patients <12 months of age, two of whom had MYCN amplification; the one without MYCN amplification was considered HR due to stage 4 refractory disease with progression in first-line therapy.